The downregulation of this pathway through CD99 knockout, may enable the regulation of the migration and invasion of GBM cells, particularly in the mesenchymal subtype, and may increase the clinical outcome, thereby improving tumor resectability and decreasing the tumor recurrence rate. This evidence concerns the gene CD99 and neoplasm.